FHTX - Foghorn Therapeutics Inc Stock Price, Fair Value and News

$5.14+0.16 (+3.21%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FHTX Price Action

Last 7 days

-3.0%

Last 30 days

-34.6%

Last 90 days

-48.5%

Trailing 12 Months

-18.1%

FHTX RSI Chart

FHTX Valuation

Market Cap

285.7M

Price/Earnings (Trailing)

-3.13

Price/Sales (Trailing)

11.2

EV/EBITDA

-2.65

Price/Free Cashflow

-2.75

FHTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FHTX Fundamentals

FHTX Revenue

Revenue (TTM)

25.5M

Rev. Growth (Yr)

-55.33%

Rev. Growth (Qtr)

13.36%

FHTX Earnings

Earnings (TTM)

-91.2M

Earnings Growth (Yr)

-33.3%

Earnings Growth (Qtr)

16.78%

FHTX Profitability

EBT Margin

-349.74%

Return on Equity

322.49%

Return on Assets

-29.58%

Free Cashflow Yield

-36.36%

FHTX Investor Care

Shares Dilution (1Y)

31.68%

Diluted EPS (TTM)

-1.92

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	33.9M	35.2M	25.5M	0
2023	20.6M	21.7M	32.6M	34.2M
2022	5.0M	9.2M	15.8M	19.2M
2021	652.3K	874.5K	1.1M	1.3M
2020	0	0	0	430.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Adrian H. B. Gottschalk
WEBSITE	https://foghorntx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	161

Foghorn Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Foghorn Therapeutics Inc? What does FHTX stand for in stocks?

FHTX is the stock ticker symbol of Foghorn Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Foghorn Therapeutics Inc (FHTX)?

As of Fri Dec 20 2024, market cap of Foghorn Therapeutics Inc is 285.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FHTX stock?

You can check FHTX's fair value in chart for subscribers.

Is Foghorn Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FHTX is over valued or under valued. Whether Foghorn Therapeutics Inc is cheap or expensive depends on the assumptions which impact Foghorn Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FHTX.

What is Foghorn Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, FHTX's PE ratio (Price to Earnings) is -3.13 and Price to Sales (PS) ratio is 11.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FHTX PE ratio will change depending on the future growth rate expectations of investors.